Braveheart Bio, Inc. (BRVE) vs Zymeworks Inc. (ZYME)

Braveheart Bio, Inc. and Zymeworks Inc. are both Biotechnology companies. Braveheart Bio, Inc. and Zymeworks Inc. are of similar size ($1.8B and $1.8B). Braveheart Bio, Inc. has negative trailing earnings, so its P/E is not meaningful; Zymeworks Inc. trades at 39.5×. Zymeworks Inc. has the higher net margin (16.3% vs 0.00%) and the higher return on invested capital (17.5% vs −28.7%). Across the 12 metrics below, Zymeworks Inc. leads on 7 and Braveheart Bio, Inc. on 5.

Valuation

Metric BRVE ZYME Biotechnology median
P/E n/m 39.48 11.36
P/S n/m 7.08 9.12
P/B 2.05 7.29 2.14
Price to free cash flow n/m n/m 26.34
EV/EBITDA n/m 33.15 0.62
EV/Sales n/m 6.70 8.56
Earnings yield (61.95%) 2.53% (34.18%)
Free cash flow yield (4.69%) (6.04%) (23.62%)

Profitability

Metric BRVE ZYME Biotechnology median
Gross margin — 51.40% 67.24%
Operating margin 0.00% 16.60% 0.00%
Net margin 0.00% 16.28% 0.00%
Free cash flow margin 0.00% (42.42%) 0.00%
Return on equity 0.00% 14.98% (50.28%)
Return on assets 0.00% 5.50% (45.89%)
Return on invested capital (28.66%) 17.49% 0.00%

Growth

Metric BRVE ZYME Biotechnology median
Revenue growth (TTM) — 97.78% 6.96%
EPS growth (last fiscal year) — 33.33% 29.86%
Revenue growth, 5-year CAGR — 22.16% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BRVE ZYME Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 21.57 3.30 4.72
Net debt to EBITDA 1.34 2.81 1.01

Dividend

Metric BRVE ZYME Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric BRVE ZYME Biotechnology median
Market cap 1.84b 1.84b 167.45m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack